Shannon N. Westin, MD, MPH, Discussed the Wee1 Inhibitor Adavosertib for PARPi-Resistant Ovarian Cancer

CancerNetwork® sat down with Shannon N. Westin, MD, MPH, at the 2021 ASCO Annual Meeting to talk about the use of adavosertib in PARP inhibitor–resistant ovarian cancer.

At the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® spoke with Shannon N. Westin, MD, MPH, of the University of Texas MD Anderson Cancer Center, about efficacy with the Wee1 inhibitor adavosertib observed in the phase 2 EFFORT trial (NCT03579316). In a patient population with a median of 4 prior lines of therapy, the agent showed a 23% overall response rate. Toxicity led to dose interruptions in most patients, but grade 3/4 adverse effects were considered to be manageable.

Here, Westin discusses how these data may be of use to the multidisciplinary team.


Similar to what we’ve seen with other combination strategies, it really is important to engage the patient, your pharmacist, and your nursing staff to make sure that everybody’s aware of the potential [adverse] effects and set expectations to really make sure patients know we may start on 1 dose, but there may be a need to hold and to reduce as needed to make this tolerable for you. I think that would be the major thing.

Now as far as where this is going. Scientifically, this is very exciting that clinically we’re seeing the benefit we need, but it’s not quite ready for primetime. We need to do a little bit more study before it’s going to be [in] the hands of clinicians out in practice.


Westin SN, Coleman RL, Fellman BM, et al. EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer. J Clin Oncol. 2021;39(suppl 15):5505. doi:10.1200/JCO.2021.39.15_suppl.5505

Related Videos
An expert from Dana-Farber Cancer Institute discusses findings from the final overall survival analysis of the phase 3 ENGOT-OV16/NOVA trial.
The use of palliative care in ovarian cancer resulted in a decrease in overall readmissions and index hospitalization costs.
Current clinical trials look to assess 177Lu-PSMA-617 in combination with other therapies including androgen deprivation therapy and docetaxel.
An expert from Dana-Farber Cancer Institute indicates that patients with prostate cancer who have 1 risk factor should undergo salvage radiotherapy following radical prostatectomy before their prostate-specific antigen level rises above 0.25 ng/ml.
An expert from Weill Cornell Medicine highlights key clinical data indicating the benefits of radium-223 in the treatment of patients with metastatic castration-resistant prostate cancer.
The risk of radionuclide exposure to the public reflects one reason urologists need to collaborate with radiation oncologists when administering radiopharmaceuticals to patients with prostate cancer.
Switching out beta emitters for alpha emitters, including radium-223, is one way to improve radiopharmaceutical treatment of prostate cancer, according to an expert from Weill Cornell Medicine.
Data demonstrate the feasibility of automated glomerular filtration rate prediction to decide between partial nephrectomy and radical nephrectomy in kidney cancer, according to an expert from the Cleveland Clinic.
Early phase trials investigating cellular therapies, bispecific antibodies, and antibody-drug conjugates for refractory kidney cancer may uncover strategies to overcome resistance mechanisms.